Merck KGaA (OTCMKTS:MKKGY – Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 61,400 shares, a growth of 6,722.2% from the March 15th total of 900 shares. Based on an average trading volume of 285,700 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold.
Merck KGaA Price Performance
Merck KGaA stock opened at $26.82 on Tuesday. The stock’s 50 day moving average is $28.03 and its 200 day moving average is $30.01. Merck KGaA has a one year low of $24.32 and a one year high of $39.17. The firm has a market cap of $17.33 billion, a P/E ratio of 16.56, a P/E/G ratio of 2.05 and a beta of 0.94. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.33 and a quick ratio of 0.91.
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.07. Merck KGaA had a net margin of 12.89% and a return on equity of 10.41%. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.40 billion. As a group, research analysts expect that Merck KGaA will post 1.87 EPS for the current year.
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
See Also
- Five stocks we like better than Merck KGaA
- Investing in Commodities: What Are They? How to Invest in Them
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- What Are Dividends? Buy the Best Dividend Stocks
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- Stock Splits, Do They Really Impact Investors?
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.